March 20th 2023
Combination treatment with nivolumab and relatlimab appears to be a safe treatment option for patients with advanced melanoma who have progressed on prior anti–PD-L1 therapy.
February 28th 2023
February 23rd 2023
Adjuvant Pembrolizumab Improves Quality-of-Life Vs Interferon α or Ipilimumab in Resected Melanoma
December 5th 2022A secondary analysis from the phase 3 SWOG S1404 trial indicated that adjuvant pembrolizumab yielded improved patient-reported outcomes compared with high-dose interferon α or ipilimumab in the treatment of patients with high-risk resected melanoma.
Pembrolizumab Granted 4 Approvals in Japan for High-Risk TNBC, RCC, and More
October 2nd 2022Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.
Adjuvant Nivolumab Yields Meaningful Improvement in RFS Vs Placebo in Stage IIB/C Melanoma
September 19th 2022The positive results from the phase 3 CheckMate76K trial suggest that recurrence-free survival may be improved following treatment with adjuvant nivolumab vs placebo in fully resected stage IIB/C melanoma.
Neoadjuvant Vs Adjuvant Pembrolizumab Yields Promising EFS Benefit in High-Risk Resectable Melanoma
September 12th 2022Patients with high-risk resectable melanoma experienced the highest event-free survival benefit when pembrolizumab was administered in the neoadjuvant settings vs the adjuvant setting
Efficacy of Naporafenib in NRAS-Mutant Unresectable/Metastatic Melanoma Presented at 2022 ESMO
September 10th 2022Results of a phase 2 trial show favorable efficacy and tolerable safety of naporafenib in combination with rineterkib, trametinib, or ribociclib in previously treated, unresectable or metastatic melanoma.
Fixed-Dose Nivolumab Plus Relatlimab Showed Consistent PFS Benefit in Metastatic Melanoma
June 6th 2022A sustained progression-free survival benefit was observed with nivolumab plus relatlimab-rmbw vs nivolumab alone in the phase 2/3 RELATIVITY-047 trial in treatment-naïve, unresectable or metastatic melanoma.
Updated Analysis of Nivolumab Plus Ipilimumab Combos Highlights Long OS for Advanced Melanoma
March 23rd 2022The 6.5-year updated analysis of the phase 3 CheckMate 067 trial highlighted notable overall survival benefit with nivolumab alone or in combination with ipilimumab for patients with advanced melanoma.
Fast Track Designation Granted to Novel Immunostimulant 7HP349 in Anti–PD-1 Resistant Melanoma
March 21st 20227HP340 was granted fast track designation in combination with an anti–CTLA-4 treatment by the FDA for patients with unresectable or malignant melanoma for whom PD-1 inhibition therapy has failed.
Adjuvant Pembrolizumab Significantly Improved DMFS Vs Placebo in Resected Stage IIB/C Melanoma
March 8th 2022The phase KEYNOTE-716 trial, which assessed the use of adjuvant pembrolizumab in patients with resected stage IIB and IIC melanoma, met its secondary end point of distant metastasis-free survival.